Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Sola | - |
dc.contributor.author | Kim, Young-Hoon | - |
dc.contributor.author | Lee, Myung-Yong | - |
dc.contributor.author | Bang, Oh Young | - |
dc.contributor.author | Jang, Sung-Won | - |
dc.contributor.author | Han, Seongwook | - |
dc.contributor.author | Park, Yoo-Jung | - |
dc.contributor.author | Kang, Seongsik | - |
dc.contributor.author | On, Young Keun | - |
dc.contributor.author | Suh, Hae Sun | - |
dc.date.accessioned | 2022-11-04T12:42:43Z | - |
dc.date.available | 2022-11-04T12:42:43Z | - |
dc.date.created | 2022-11-04 | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/144654 | - |
dc.description.abstract | Reduced-dose nonvitamin K antagonist oral anticoagulants (NOACs) are commonly prescribed to Asian patients with nonvalvular atrial fibrillation (NVAF). We aimed to compare the risk of stroke/systemic embolism (S/SE) and major bleeding (MB) between patients treated with reduced-dose NOACs and those treated with warfarin, using the claims database in Korea. Patients with NVAF newly initiated on oral anticoagulants (OACs; apixaban, dabigatran, rivaroxaban, and warfarin) between 1 July 2015 and 30 November 2016 were included. Among all patients with NVAF treated with OACs, 5249, 6033, 7602, and 8648 patients were treated with reduced-dose apixaban, dabigatran, rivaroxaban, and warfarin, respectively. Patients treated with reduced-dose NOACs were older and had higher CHA(2)DS(2)-VASc and HAS-BLED scores than those treated with warfarin. Compared to warfarin, all reduced-dose NOACs showed significantly lower risk of S/SE (hazard ratios (95% confidence interval), 0.63 (0.52-0.75) for apixaban; 0.51 (0.42-0.61) for dabigatran; and 0.67 (0.57-0.79) for rivaroxaban) and MB (0.54 (0.45-0.65) for apixaban; 0.58 (0.49-0.69) for dabigatran; 0.73 (0.63-0.85) for rivaroxaban). In the real-world practice among Asians with NVAF, all reduced-dose NOACs were associated with a significantly lower risk of S/SE and MB compared to those of warfarin. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | ASIAN PATIENTS | - |
dc.subject | STROKE PREVENTION | - |
dc.subject | THERAPY | - |
dc.subject | INTENSITY | - |
dc.subject | DISEASE | - |
dc.subject | SAFETY | - |
dc.subject | UPDATE | - |
dc.title | Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Young-Hoon | - |
dc.identifier.doi | 10.3390/jcm10173918 | - |
dc.identifier.scopusid | 2-s2.0-85113855196 | - |
dc.identifier.wosid | 000694394000001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, v.10, no.17 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.title | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.volume | 10 | - |
dc.citation.number | 17 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | ASIAN PATIENTS | - |
dc.subject.keywordPlus | STROKE PREVENTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | INTENSITY | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | UPDATE | - |
dc.subject.keywordAuthor | anticoagulants | - |
dc.subject.keywordAuthor | atrial fibrillation | - |
dc.subject.keywordAuthor | NOAC | - |
dc.subject.keywordAuthor | stroke | - |
dc.subject.keywordAuthor | systemic embolism | - |
dc.subject.keywordAuthor | warfarin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.